CU23011A1 - Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones - Google Patents

Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones

Info

Publication number
CU23011A1
CU23011A1 CU2000024220000242A CU20000242A CU23011A1 CU 23011 A1 CU23011 A1 CU 23011A1 CU 2000024220000242 A CU2000024220000242 A CU 2000024220000242A CU 20000242 A CU20000242 A CU 20000242A CU 23011 A1 CU23011 A1 CU 23011A1
Authority
CU
Cuba
Prior art keywords
structures
resulting
reactivity
formulations
antigenic structures
Prior art date
Application number
CU2000024220000242A
Other languages
English (en)
Inventor
Cano Carlos Duarte Cano Carlos Duarte
Perez Enrique Iglesias Perez Enrique Iglesias
Ricondo Luis Javier Cruz Ricondo Luis Javier Cruz
Rubido Julio Cesar Aguilar Rubido Julio Ce Aguilar
Perez Hilda Elisa Garay Perez Hilda Elisa Garay
Acosta Osvaldo Reyes Acosta Osvaldo Reyes
Nieto Gerardo Enrique Guillen Nieto Gerard Guillen
Gonzalez Verena Lucila Muzio Gonzalez Verena Muzio
Arias Eduardo Penton Arias Eduardo Penton
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU2000024220000242A priority Critical patent/CU23011A1/es
Priority to MYPI20015012A priority patent/MY137709A/en
Priority to MXPA03003849A priority patent/MXPA03003849A/es
Priority to KR1020027008651A priority patent/KR100887591B1/ko
Priority to BR0107424-5A priority patent/BR0107424A/pt
Priority to ARP010105120A priority patent/AR031182A1/es
Priority to HK04101011.9A priority patent/HK1058154B/xx
Priority to EP01983427A priority patent/EP1334727A2/en
Priority to CA002427539A priority patent/CA2427539A1/en
Priority to JP2002538969A priority patent/JP4099059B2/ja
Priority to AU2002214938A priority patent/AU2002214938B2/en
Priority to PCT/CU2001/000007 priority patent/WO2002036160A2/es
Priority to EA200300535A priority patent/EA005313B1/ru
Priority to CNB018039782A priority patent/CN100387616C/zh
Priority to AU1493802A priority patent/AU1493802A/xx
Priority to ZA200205236A priority patent/ZA200205236B/en
Publication of CU23011A1 publication Critical patent/CU23011A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con el método pLa presente invención se relaciona con el método para la obtención de estructuras antigiénicas de alara la obtención de estructuras antigiénicas de alta reactividad cruzada, capaces de potenciar la reta reactividad cruzada, capaces de potenciar la respuesta inmune a antíjenos peptídios administradosspuesta inmune a antíjenos peptídios administrados par vía sistémica y/o mucosal, generando potentes par vía sistémica y/o mucosal, generando potentes respuestas inmunes así coma estructuras químicas respuestas inmunes así coma estructuras químicas resultantes de la aplicación de este método, formuresultantes de la aplicación de este método, formulaciones obtenidas a partir de dichas estructuras laciones obtenidas a partir de dichas estructuras y uso de las mismas. El método describe la obtenciy uso de las mismas. El método describe la obtención de nuevas estructuras dendriméricas. Partiendo ón de nuevas estructuras dendriméricas. Partiendo de la selección y síntesis de dendrímeros, que posde la selección y síntesis de dendrímeros, que posteriormente son acoplados a moléculas portadoras. teriormente son acoplados a moléculas portadoras. Las estructuras resultantes pueden utilizarse convLas estructuras resultantes pueden utilizarse convenientemente adyuvadas o en una formulación donde enientemente adyuvadas o en una formulación donde pueden introducirse varios antígenos de este tipo,pueden introducirse varios antígenos de este tipo, encontrándose un efecto sinérgico entre estos com encontrándose un efecto sinérgico entre estos componentes con respecto a la reactividad cruzada y lponentes con respecto a la reactividad cruzada y la inmunogenicidad de la respuesta obtenida. Ademása inmunogenicidad de la respuesta obtenida. Además la preparación puede contener, estabilizadores y la preparación puede contener, estabilizadores y preservos. Las estructuras antigénicas resultantespreservos. Las estructuras antigénicas resultantes son aplicables en la industria farmacéutica como son aplicables en la industria farmacéutica como formulaciones vacúnales tanto para uso humano comoformulaciones vacúnales tanto para uso humano como veterinario y coma parte de sistemas de diagnósti veterinario y coma parte de sistemas de diagnóstico. co.
CU2000024220000242A 2000-11-03 2000-11-03 Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones CU23011A1 (es)

Priority Applications (16)

Application Number Priority Date Filing Date Title
CU2000024220000242A CU23011A1 (es) 2000-11-03 2000-11-03 Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones
MYPI20015012A MY137709A (en) 2000-11-03 2001-10-30 Method for obtaining antigenic structures of high cross reactivity and their use in formulations
MXPA03003849A MXPA03003849A (es) 2000-11-03 2001-11-01 Metodo de obtencion de estructuras antigenicas que potencian la reactividad cruzada especifica.
KR1020027008651A KR100887591B1 (ko) 2000-11-03 2001-11-01 특정의 교차 반응성을 증가시키는 항원성 구조들의 제조방법
BR0107424-5A BR0107424A (pt) 2000-11-03 2001-11-01 Método para obtenção de estruturas antigênicas, estruturas antigênica, uso da mesma, formulação de vacina, e, uso da mesma
ARP010105120A AR031182A1 (es) 2000-11-03 2001-11-01 Metodo de obtencion de estructuras antigenicas que potencian la reactividad cruzada especifica y su uso en formulaciones
HK04101011.9A HK1058154B (en) 2000-11-03 2001-11-01 Method for obtaining antigenic structures enhancing specific cross reactivity
EP01983427A EP1334727A2 (en) 2000-11-03 2001-11-01 Method for obtaining antigenic structures enhancing specific cross reactivity
CA002427539A CA2427539A1 (en) 2000-11-03 2001-11-01 Method for obtaining antigenic structures enhancing specific cross reactivity
JP2002538969A JP4099059B2 (ja) 2000-11-03 2001-11-01 特定交叉反応性を高める抗原構造を得る方法
AU2002214938A AU2002214938B2 (en) 2000-11-03 2001-11-01 Method for obtaining antigenic structures enhancing specific cross reactivity
PCT/CU2001/000007 WO2002036160A2 (es) 2000-11-03 2001-11-01 Método de obtención de estructuras antigénicas que potencian la reactividad cruzada específica
EA200300535A EA005313B1 (ru) 2000-11-03 2001-11-01 Способ получения антигенных структур, усиливающих специфическую перекрестную реактивность
CNB018039782A CN100387616C (zh) 2000-11-03 2001-11-01 获得可增强特异交叉反应性的抗原结构的方法
AU1493802A AU1493802A (en) 2000-11-03 2001-11-01 Method for obtaining antigenic structures enhancing specific cross reactivity
ZA200205236A ZA200205236B (en) 2000-11-03 2002-06-28 Method for obtaining antigenic structures enhancing specific cross reactivity.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2000024220000242A CU23011A1 (es) 2000-11-03 2000-11-03 Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones

Publications (1)

Publication Number Publication Date
CU23011A1 true CU23011A1 (es) 2004-12-17

Family

ID=5459562

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2000024220000242A CU23011A1 (es) 2000-11-03 2000-11-03 Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones

Country Status (14)

Country Link
EP (1) EP1334727A2 (es)
JP (1) JP4099059B2 (es)
KR (1) KR100887591B1 (es)
CN (1) CN100387616C (es)
AR (1) AR031182A1 (es)
AU (2) AU2002214938B2 (es)
BR (1) BR0107424A (es)
CA (1) CA2427539A1 (es)
CU (1) CU23011A1 (es)
EA (1) EA005313B1 (es)
MX (1) MXPA03003849A (es)
MY (1) MY137709A (es)
WO (1) WO2002036160A2 (es)
ZA (1) ZA200205236B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
DE102007002726A1 (de) * 2007-01-18 2008-07-31 Bayer Schering Pharma Aktiengesellschaft Neue Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
WO2008151389A1 (en) * 2007-06-15 2008-12-18 Macfarlane Burnet Institute For Medical Research And Public Health Limited Chemically modified macromolecules
PL230663B1 (pl) 2015-01-15 2018-11-30 Univ Gdanski Szczepionka, sposob jej otrzymywania, wyizolowane chimeryczne bialko, wektor ekspresyjny, zestaw zawierajacy szczepionke oraz kompozycja do zastosowania w profilaktyce zakazen powodowanych przez HCV i/lub HBV
KR20220119051A (ko) * 2019-12-02 2022-08-26 엔리티사 (상하이) 파마슈티컬 컴퍼니 리미티드 신규한 다기능성 올리고펩타이드
US20240218016A1 (en) * 2019-12-02 2024-07-04 Shenzhen Institutes Of Advanced Technology Peptides and their use in the treatment of inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2054678T5 (es) * 1986-08-18 1997-09-16 Dow Chemical Co Conjugados estrella.
CU22629A1 (es) * 1997-03-06 2000-12-22 Ct Ingenieria Genetica Biotech Formulaciones inmunopotenciadoras para uso vacunal

Also Published As

Publication number Publication date
MY137709A (en) 2009-02-27
AU1493802A (en) 2002-05-15
KR20020080360A (ko) 2002-10-23
WO2002036160A3 (es) 2003-05-30
CN100387616C (zh) 2008-05-14
CN1446094A (zh) 2003-10-01
EP1334727A2 (en) 2003-08-13
MXPA03003849A (es) 2004-10-15
HK1058154A1 (en) 2004-05-07
EA005313B1 (ru) 2004-12-30
WO2002036160A2 (es) 2002-05-10
AU2002214938B2 (en) 2006-04-13
ZA200205236B (en) 2003-09-29
JP2004513897A (ja) 2004-05-13
AR031182A1 (es) 2003-09-10
JP4099059B2 (ja) 2008-06-11
EA200300535A1 (ru) 2003-10-30
BR0107424A (pt) 2002-10-15
KR100887591B1 (ko) 2009-03-10
CA2427539A1 (en) 2003-05-01

Similar Documents

Publication Publication Date Title
ES2139879T5 (es) Adyuvante de la mucosa no toxico.
ES2263668T3 (es) Composicion de vacuna que comprende un antigeno y un peptido con propiedades adyuvantes.
DK1361890T3 (da) Influenzavaccineformuleringer til intradermal indgift
EP0283085A1 (en) Adjuvant mixture
NO20023829L (no) Proteosom influensavaksine
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
BR0312792A (pt) Composições de vacinas contendo séries antigênicas de amilóide beta1-6
KR20130112790A (ko) 백신 조성물
Abdel-Aal et al. Structure–activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates
NO20011586D0 (no) Nye metoder for terapeutisk vaksinasjon
Schulze et al. Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection
AR031182A1 (es) Metodo de obtencion de estructuras antigenicas que potencian la reactividad cruzada especifica y su uso en formulaciones
Yang et al. Anti-caries vaccine based on clinical cold-adapted influenza vaccine: A promising alternative for scientific and public-health protection against dental caries
Glück et al. Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems
Zeng et al. Characterisation of the antibody response to a totally synthetic immunocontraceptive peptide vaccine based on LHRH
SE9604296D0 (sv) New pharmaceutical formulation of polypeptides
Zeng et al. Lipidation of intact proteins produces highly immunogenic vaccine candidates
ES2541443T3 (es) Adyuvantes peptídicos
JP2004519453A5 (es)
Bragazzi et al. Vaccine adjuvants: history, role, mechanisms of action, and side effects
AR031437A1 (es) Metodo de obtencion de agregados antigenicos y su uso en formulaciones
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
ES2571055B1 (es) Conjugado amiloide y usos y procedimientos del mismo
Acosta et al. TB VACCINES BASED ON PROTEOLIPOSOMES AND LIPOSOMES FROM NON PATHOGENIC MYCOBACTERIA
TH57388A (th) วิธี เพื่อให้ได้โครงสร้างก่อภูมิคุ้มกันที่มีความสามารถทำปฏิกิริยาข้ามสูง และการใช้ของมันในสารผสมตามสูตร